SCHEMBL21610985

SCHEMBL21610985

Clc1cc(Cl)c2c(I)c[nH]c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.46
MAP4K4 O95819 3/20 0.34
PIM1 P11309 3/20 0.34
CLK2 P49760 3/20 0.34
GSK3B P49841 3/20 0.34
DYRK1A Q13627 3/20 0.34
CLK4 Q9HAZ1 3/20 0.34
CDC7 O00311 2/20 0.34
DAPK3 O43293 2/20 0.34
PRKD3 O94806 2/20 0.34
PAK4 O96013 2/20 0.34
PRKACA P17612 2/20 0.34
CSNK1A1 P48729 2/20 0.34
CDK7 P50613 2/20 0.34
CDK9 P50750 2/20 0.34
PRKX P51817 2/20 0.34
CDK5 Q00535 2/20 0.34
MAP4K2 Q12851 2/20 0.34
ROCK1 Q13464 2/20 0.34
STK3 Q13188 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31343187 0.82 HSP90AA1 (0.39) MAP4K4PIM1CLK2GSK3BDYRK1A
SCHEMBL22252550 0.82 HSP90AA1 (0.39) MAP4K4PIM1CLK2GSK3BDYRK1A
SCHEMBL14158956 0.81 CHEK1 (0.43) CHEK1MAPK1LRRK2HSP90AA1HSP90AB1
SCHEMBL31347233 0.73 KDM4E (0.46) CHEK1MAP2K1
SCHEMBL26104506 0.73 KDM4E (0.46) CHEK1MAP2K1
SCHEMBL20588419 0.73 HSP90AB1 (0.39) MAP4K4PIM1CLK2GSK3BDYRK1A
SCHEMBL16177859 0.73 LRRK2 (0.57) ROCK1ROCK2LRRK2HSP90AA1HSP90AB1
SCHEMBL1017711 0.71 CHEK1 (0.56) CHEK1MAPK1CHUK
SCHEMBL16177731 0.70 CHUK (0.53) ROCK1ROCK2LRRK2HSP90AA1HSP90AB1
SCHEMBL30668735 0.69 LRRK2 (0.57) CHEK1MAP4K4PIM1CLK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240844-B2 Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease VORONOI, INC. (KR) 2025-03-04 US disclosed
CN-119431362-A Substituted heteroaryl carboxylic acid compound, preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2025-02-14 CN disclosed
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOIBIO INC. (KR) 2023-06-15 US disclosed
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT VORONOIBIO INC. (KR) 2023-06-15 US disclosed
EP-3604304-B1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) 2022-09-07 EP disclosed
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2022-04-07 US disclosed
US-20220064161-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE VORONOI, INC. (KR) 2022-03-03 US disclosed
US-20220064161-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE VORONOI, INC. (KR) 2022-03-03 US disclosed
EP-3915986-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Voronoi Inc. (KR) 2021-12-01 EP disclosed
EP-3915985-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE Voronoi Co., Ltd. (KR) 2021-12-01 EP disclosed
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION 2021-09-14 US disclosed
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION 2021-09-14 US disclosed
CN-110662745-B Pyrrolopyridine derivatives, process for producing the same, and pharmaceutical composition for preventing or treating protein kinase-associated diseases 大邱庆北尖端医疗产业振兴财团 2021-08-03 CN disclosed
WO-2020185044-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 주식회사 보로노이 2020-09-17 WO disclosed
WO-2020149715-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE 주식회사 보로노이 2020-07-23 WO disclosed
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-07-02 US disclosed
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-07-02 US disclosed
EP-3604304-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2020-02-05 EP disclosed
CN-110662745-A Pyrrolopyridine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating protein kinase-associated diseases comprising the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2020-01-07 CN disclosed
WO-2018174650-A9 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES 재단법인 대구경북첨단의료산업진흥재단 2020-01-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240844-B2 Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease CLK1, CLK2, CLK3 CHEK1 176/4885MAP4K4 203/4885PIM1 561/4885
US-20230183243-A1 HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT TTK, TTBK1, TTBK2 CHEK1 27/4885MAP4K4 274/4885PIM1 2644/4885
US-20220064161-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE CLK1, CLK2, CLK3 CHEK1 179/4885MAP4K4 205/4885PIM1 551/4885
US-20220106307-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DYRK1A, DYRK2, DYRK1B CHEK1 893/4885MAP4K4 133/4885PIM1 639/4885
US-11117892-B2 Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases DYRK1A, DYRK2, DYRK1B CHEK1 893/4885MAP4K4 133/4885PIM1 639/4885
US-20200207756-A1 PYRROLO-PYRIDINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES DYRK1A, DYRK2, DYRK4 CHEK1 970/4885MAP4K4 98/4885PIM1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.